Logo image of TVTX

TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis

NASDAQ:TVTX - US89422G1076 - Common Stock

19.61 USD
+1.46 (+8.04%)
Last: 9/3/2025, 8:00:01 PM
19.61 USD
0 (0%)
After Hours: 9/3/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TVTX. TVTX was compared to 542 industry peers in the Biotechnology industry. TVTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TVTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TVTX has reported negative net income.
In the past year TVTX has reported a negative cash flow from operations.
TVTX had negative earnings in each of the past 5 years.
TVTX had a negative operating cash flow in each of the past 5 years.
TVTX Yearly Net Income VS EBIT VS OCF VS FCFTVTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

TVTX's Return On Assets of -30.44% is fine compared to the rest of the industry. TVTX outperforms 66.42% of its industry peers.
The Return On Equity of TVTX (-516.25%) is worse than 78.04% of its industry peers.
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROIC N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
TVTX Yearly ROA, ROE, ROICTVTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 96.89%, TVTX belongs to the top of the industry, outperforming 95.94% of the companies in the same industry.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
TVTX Yearly Profit, Operating, Gross MarginsTVTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TVTX has more shares outstanding
TVTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TVTX has a worse debt to assets ratio.
TVTX Yearly Shares OutstandingTVTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TVTX Yearly Total Debt VS Total AssetsTVTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TVTX has an Altman-Z score of -1.78. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
TVTX's Altman-Z score of -1.78 is in line compared to the rest of the industry. TVTX outperforms 54.06% of its industry peers.
TVTX has a Debt/Equity ratio of 9.50. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 9.50, TVTX is doing worse than 83.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Altman-Z -1.78
ROIC/WACCN/A
WACC9.23%
TVTX Yearly LT Debt VS Equity VS FCFTVTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

TVTX has a Current Ratio of 2.00. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
TVTX has a Current ratio of 2.00. This is in the lower half of the industry: TVTX underperforms 74.54% of its industry peers.
TVTX has a Quick Ratio of 1.98. This is a normal value and indicates that TVTX is financially healthy and should not expect problems in meeting its short term obligations.
TVTX's Quick ratio of 1.98 is on the low side compared to the rest of the industry. TVTX is outperformed by 73.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.98
TVTX Yearly Current Assets VS Current LiabilitesTVTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.11% over the past year.
Looking at the last year, TVTX shows a very strong growth in Revenue. The Revenue has grown by 87.94%.
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%

3.2 Future

The Earnings Per Share is expected to grow by 27.71% on average over the next years. This is a very strong growth
Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 37.60% on average per year.
EPS Next Y72.11%
EPS Next 2Y44.18%
EPS Next 3Y34.88%
EPS Next 5Y27.71%
Revenue Next Year80.63%
Revenue Next 2Y60.82%
Revenue Next 3Y50.16%
Revenue Next 5Y37.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TVTX Yearly Revenue VS EstimatesTVTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
TVTX Yearly EPS VS EstimatesTVTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

TVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 60.65, which means the current valuation is very expensive for TVTX.
Based on the Price/Forward Earnings ratio, TVTX is valued cheaper than 88.93% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.48. TVTX is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 60.65
TVTX Price Earnings VS Forward Price EarningsTVTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVTX Per share dataTVTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

TVTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 34.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.18%
EPS Next 3Y34.88%

More info and screens

0

5. Dividend

5.1 Amount

TVTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRAVERE THERAPEUTICS INC

NASDAQ:TVTX (9/3/2025, 8:00:01 PM)

After market: 19.61 0 (0%)

19.61

+1.46 (+8.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners116.52%
Inst Owner Change2.49%
Ins Owners0.84%
Ins Owner Change4.08%
Market Cap1.75B
Analysts84.55
Price Target34.76 (77.26%)
Short Float %14.11%
Short Ratio8.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.29%
Min EPS beat(2)14.67%
Max EPS beat(2)53.91%
EPS beat(4)2
Avg EPS beat(4)10.07%
Min EPS beat(4)-27.29%
Max EPS beat(4)53.91%
EPS beat(8)3
Avg EPS beat(8)-90.06%
EPS beat(12)5
Avg EPS beat(12)-61.8%
EPS beat(16)5
Avg EPS beat(16)-51.58%
Revenue beat(2)2
Avg Revenue beat(2)8.78%
Min Revenue beat(2)6.09%
Max Revenue beat(2)11.48%
Revenue beat(4)3
Avg Revenue beat(4)4.88%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)11.48%
Revenue beat(8)5
Avg Revenue beat(8)-5.3%
Revenue beat(12)8
Avg Revenue beat(12)-5.78%
Revenue beat(16)9
Avg Revenue beat(16)-10.15%
PT rev (1m)1.29%
PT rev (3m)1.22%
EPS NQ rev (1m)-16.69%
EPS NQ rev (3m)-7.3%
EPS NY rev (1m)-3.38%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)6.33%
Revenue NQ rev (3m)8.75%
Revenue NY rev (1m)6.79%
Revenue NY rev (3m)5.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 60.65
P/S 5.24
P/FCF N/A
P/OCF N/A
P/B 53.38
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)0.32
Fwd EY1.65%
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS3.75
BVpS0.37
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.44%
ROE -516.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.89%
FCFM N/A
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 9.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.47%
Cap/Sales 12.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.98
Altman-Z -1.78
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.62%
EPS Next Y72.11%
EPS Next 2Y44.18%
EPS Next 3Y34.88%
EPS Next 5Y27.71%
Revenue 1Y (TTM)87.94%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%111.49%
Revenue Next Year80.63%
Revenue Next 2Y60.82%
Revenue Next 3Y50.16%
Revenue Next 5Y37.6%
EBIT growth 1Y46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.54%
EBIT Next 3Y37.49%
EBIT Next 5Y33.79%
FCF growth 1Y45.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.8%
OCF growth 3YN/A
OCF growth 5YN/A